Role of RLIP76 in doxorubicin resistance in lung cancer (review)

International Journal of Oncology

Volumn 34, Issue 6, 2009, Pages 1505-1511

  Vatsyayan, Rit ^a   Chaudhary, Pankaj ^a   Lelsani, Poorna Chandra Rao ^a   Singhal, Preeti ^a   Awasthi, Yogesh C ^a   Awasthi, Sanjay ^a   Singhal, Sharad S ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Cancer; Doxorubicin; Drug resistance; Glutathione conjugate transport; PKC ; RLIP76

Indexed keywords

ABC TRANSPORTER; CARRIER PROTEIN; CELL PROTEIN; DOXORUBICIN; HEAT SHOCK TRANSCRIPTION FACTOR 1; PROTEIN KINASE C ALPHA; PROTEIN POB 1; PROTEIN RLIP 76; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL TRANSPORT; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG TRANSPORT; GENE SEQUENCE; HEAT SHOCK; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RADIOSENSITIVITY; REVIEW; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SITE DIRECTED MUTAGENESIS; TRANSPORT KINETICS;

ANTIBIOTICS, ANTINEOPLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GTPASE-ACTIVATING PROTEINS; HUMANS; LUNG NEOPLASMS;

EID: 67649427320     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000279     Document Type: Review

References (58)

1. Arriagada R, Le Péchoux C and Pignon JP: Resected non-small cell lung cancer: need for adjuvant lymph node treatment? From hope to reality. Lung Cancer 42: S57-S64, 2003.
2. Hoffman PC, Mauer AM and Vokes EE: Lung cancer. Lancet 355: 479-485, 2000.
3. Dalpiaz O, al Rabi N, Galfano A, Martignoni G, Ficarra V and Artibani W: Small cell carcinoma of the bladder: a case report and a literature review. Arch Esp Urol 56: 197-202, 2003.
4. Filipits M, Pohl G, Stranzl T, et al: Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma. Clin Cancer Res 9: 820-826, 2003.
5. Volm M, Koomagi R and Rittgen W: Cellular predictive factors of drug resistance in non-small cell lung carcinomas. Methods Mol Med 75: 39-51, 2003.
6. Pikula S, Hayden JB, Awasthi S, Awasthi YC and Zimniak P: Organic anion-transporting ATPase of rat liver. I. Purification, photoaffinity labeling, and regulation by phosphorylation. J Biol Chem 269: 27566-27573, 1994.
7. Singhal SS, Yadav S, Singhal J, Drake K, Awasthi YC and Awasthi S: The role of PKCα and RLIP76 in transport-mediated doxorubicin-resistance in lung cancer. FEBS Lett 579: 4635-4641, 2005.
8. Awasthi S, Singhal SS, Sharma R, Zimniak P and Awasthi YC: Transport of glutathione-conjugates and chemotherapeutic drugs by RLIP76: a novel link between G-protein and tyrosine kinase signaling and drug resistance. Int J Cancer 106: 635-646, 2003.
9. Awasthi S, Cheng J, Singhal SS, et al: Novel function of human RLIP76: ATP-dependent transport of glutathione-conjugates and doxorubicin. Biochemistry 39: 9327-9334, 2000.
10. Jullien-Flores V, Dorseuil O, Romero F, et al: Bridging Ral-GTPase to Rho-pathways. RLIP76, a Ral-effector with CDC42/Rac GTPase-activating protein activity. J Biol Chem 270: 22473-22477, 1995.
11. Cantor SB, Urano T and Feig LA: Identification and characterization of Ral-binding-protein1, a potential downstream target of Ral GTPases. Mol Cell Biol 15: 4578-4584, 1995.
12. Park SH and Weinberg RA: A putative effector of Ral has homology to Rho/ Rac GTPase activating proteins. Oncogene 11: 2349-2355, 1995.
13. Jullien-Flores V, Mahe Y, Mirey G, et al: RLIP76, an effector of the GTPase Ral, interacts with the AP2 complex: involvement of the Ral pathway in receptor-endocytosis. J Cell Sci 113: 2837-2844, 2003.
14. Mirey G, Balakireva M, L'Hoste S, Rosse C, Voegeling S and Camonis J: A Ral guanine exchange factor-Ral pathway is conserved in Drosophila melanogaster and sheds new light on the connectivity of the Ral, Ras and Rap-pathways. Mol Cell Biol 23: 1112-1124, 2003.
15. www.ensembl.org human/exon report.
16. Quaroni A and Paul EC: Cytocentrin is a Ral-binding protein involved in the assembly and function of the mitotic-apparatus. J Cell Sci 112: 707-718, 1999.
17. Singhal SS, Singhal J, Sharma R, et al: Role of RLIP76 in lung cancer doxorubicin-resistance: I The ATPase activity of RLIP76 correlates with doxorubicin and 4HNE-resistance in lung cancer cells. Int J Oncol 22: 365-375, 2003.
18. Singhal SS, Awasthi YC and Awasthi S: Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res 66: 2354-2360, 2006.
19. Awasthi S, Cheng JZ, Singhal SS, et al: Functional reassembly of ATP-dependent xenobiotic transport by the N- and C-terminal domains of RLIP76 and identification of ATP binding sequences. Biochemistry 40: 4159-4168, 2001.
20. Yadav S, Singhal SS, Singhal J, et al: Identification of membrane-anchoring domains of RLIP76 using deletion mutant analysis. Biochemistry 43: 16243-16253, 2004.
21. Yadav S, Zajac E, Singhal SS and Awasthi S: Linking stress-signaling, glutathione metabolism, signaling pathways and xenobiotic transporters. Cancer Metastasis Rev 26: 59-69, 2007.
22. Awasthi S, Sharma R, Singhal SS, Zimniak P and Awasthi YC: RLIP76, a novel transporter catalyzing ATP-dependent efflux of xenobiotics. Drug Metab Dispos 30: 1300-1310, 2002.
23. Hu Y and Mivechi NF: HSF-1 interacts with Ral-binding-protein 1 in a stress-responsive, multi-protein complex with HSP90 in vivo. J Biol Chem 278: 17299-17306, 2003.
24. Oosterhoff JK, Penninkhof F, Brinkmann AO, Grootegoed JA and Blok LG: POB1 is down-regulated during human prostate cancer progression and inhibits growth factor signaling in prostate cancer cells. Oncogene 22: 2920-2925, 2003.
25. Singhal SS, Yadav S, Drake K, Singhal J and Awasthi S: Hsf-1 and POB1 induce drug-sensitivity and apoptosis by inhibiting Ralbp1. J Biol Chem 283: 19714-19729, 2008.
26. Rosse C, L'Hoste S, Offner N, Picard A and Camonis JH: RLIP76, an effector of the Ral-GTPases, is a platform for Cdk1 to phosphorylate epsin during the switch off of endocytosis in mitosis. J Biol Chem 278: 30597-30604, 2003.
27. Ikeda M, Ishida O, Hinoi T, Kishida S and Kikuchi AJ: Identification and characterization of a novel protein interacting with Ral-binding protein 1, a putative effector protein of Ral. J Biol Chem 273: 814-821,1998.
28. Awasthi S, Singhal SS, Srivastava SK, et al: Adenosine-triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein. J Clin Invest 93: 958-965, 1994.
29. Awasthi S, Singhal SS, Srivastava SK, et al: ATP dependent human erythrocyte glutathione-conjugate-transporter. I. Purification, photoaffinity-labeling, and kinetic characteristics of ATPase-activity. Biochemistry 37: 5231-5238, 1998.
30. Awasthi S, Singhal SS, Pikula S, et al: ATP-dependent human erythrocyte glutathione-conjugate-transporter. II. Functional reconstitution of transport-activity. Biochemistry 37: 5239-5248, 1998.
31. Sharma R, Singhal SS, Cheng J, et al: RLIP76 is the major ATP-dependent transporter of glutathione-conjugates and doxorubicin in human erythrocytes. Arch Biochem Biophys 391: 171-179, 2001.
32. Cheng J, Sharma R, Yang Y, et al: Accelerated metabolism and exclusion of 4-hydroxy-nonenal through induction of RLIP76 and hGST5.8 is an early adaptive response of cells to heat and oxidative-stress. J Biol Chem 276: 41213-41223, 2001.
33. Awasthi S, Singhal SS, Yadav S, et al: RLIP76 is a major determinant of radiation-sensitivity. Cancer Res 65: 6022-6028, 2005.
34. Singhal J, Singhal SS, Yadav S, et al: RLIP76 in defense of radiation poisoning. Int J Rad Oncol Biol Phys 72: 553-561, 2008.
35. Sharma R, Singhal SS, Wickramarachchi D, Awasthi YC and Awasthi S: RLIP76 mediated transport of leukotrienes C4 (LTC4) in cancer cells: implications in drug resistance. Int J Cancer 112: 934-942, 2004.
36. Stuckler D, Singhal J, Singhal SS, Yadav S, Awasthi YC and Awasthi S: RLIP76 transports vinorelbine and mediates drug-resistance in non-small cell lung cancer. Cancer Res 65: 991-998, 2005.
37. Awasthi S, Singhal SS, Pandya U, Gopal S, Zimniak P, Singh SV and Awasthi YC: ATP-dependent colchicine transport by human erythrocyte glutathione-conjugate transporter. Toxicol Appl Pharmacol 155: 215-226, 1999.
38. Singhal SS, Sehrawat A, Metha A, Sahu M and Awasthi S: Functional reconstitution of RLIP76 catalyzing ATP-dependent transport of glutathione-conjugate. Int J Oncol 34: 191-199, 2009.
39. Goldin A, Venditti JM and Geran R: The effectiveness of the anthracycline analog 4′-epidoxorubicin in the treatment of experimental tumors: a review. Invest New Drugs 3: 3-21, 1985.
40. Booser DJ and Hortobagyi GN: Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drug 47: 223-258, 1994.
41. Singal PK, Siveski-Iliskovic N, Hill M, Thomas TP and Li T: Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol 27: 1055-1063, 1995.
42. Yeh GC, Daschner PJ, Lopaczynska J, MacDonald CJ and Ciolino HP: Modulation of glucose-6-phosphate dehydrogenase activity and expression is associated with aryl hydrocarbon resistance in vitro. J Biol Chem 276: 34708-34713, 2001.
43. Zwelling LA, Slovak ML, Doroshow JH, et al: HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II. Natl Cancer Inst 82: 1553-1561, 1990.
44. Song SH, Lee KH, Kang MS and Lee YJ: Role of paxillin in metabolic oxidative stress-induced cytoskeletal reorganization: involvement of SAPK signals transduction pathway and PTPPEST gene expression. Free Radic Biol Med 29: 61-70, 2000.
45. Kok JW, Veldman RJ, Klappe K, Koning H, Filipeanu CM and Muller M: Differential expression of sphingolipids in MRP1 over-expressing HT29 cells. Int J Cancer 87: 172-178, 2000.
46. Borst P, Evers R, Kool M and Wijnholds J: The multidrug resistance protein family. Biochim Biophys Acta 1461: 347-357, 1999.
47. Cole SP, Bhardwaj G, Gerlach JH, et al: Over-expression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
48. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
49. Lai SL, Goldstein LJ, Gottesman MM, et al: MDR1 gene expression in lung cancer. J Natl Cancer Inst 81: 1144-1150, 1989.
50. Hendrikse NH: Monitoring interactions at ATP-dependent drug efflux pumps. Curr Pharm Des 6: 1653-1668, 2000.
51. Awasthi S, Singhal SS, Singhal J, Cheng J, Zimniak P and Awasthi YC: Role of RLIP76 in lung cancer doxorubicin resistance II. Doxorubicin transport in lung cancer by RLIP76. Int J Oncol 22: 713-720, 2003.
52. Singhal SS, Singhal J, Nair MP, Lacko AG, Awasthi YC and Awasthi S: Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol 30: 717-725, 2007.
53. Singhal SS, Yadav S, Singhal J, Sahu M, Sehrawat A and Awasthi S: Diminished drug transport and augmented radiation sensitivity caused by loss of RLIP76. FEBS Lett 582: 3408-3414, 2008.
54. Singhal SS, Wickramarachchi D, Singhal J, Yadav S, Awasthi YC and Awasthi S: Determinants of differential doxorubicin sensitivity between SCLC and NSCLC. FEBS Lett 580: 2258-2264, 2006.
55. Awasthi S, Singhal SS, Singhal J, Yang Y, Zimniak P and Awasthi YC: Role of RLIP76 in lung cancer doxorubicin resistance III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity. Int J Oncol 22: 721-732, 2003.
56. Singhal SS, Yadav S, Singhal J, Awasthi YC and Awasthi S: Mitogenic and drug-resistance mediating effects of PKCα require RLIP76. Biochem Biophys Res Commun 348: 722-727, 2006.
57. Yadav S, Zajac E, Singhal SS, et al: POB1 over-expression inhibits RLIP76-mediated transport of glutathione-conjugates, drugs and promotes apoptosis. Biochem Biophys Res Commun 328: 1003-1009, 2005.
58. Singhal SS, Yadav S, Singhal J, Zajac E, Awasthi YC and Awasthi S: Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. Biochem Pharmacol 70: 481-488, 2005.